MCID: SKN022
MIFTS: 61

Skin Squamous Cell Carcinoma

Categories: Cancer diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Skin Squamous Cell Carcinoma

MalaCards integrated aliases for Skin Squamous Cell Carcinoma:

Name: Skin Squamous Cell Carcinoma 11 14
Squamous Cell Carcinoma of Skin 11 71 33
Scc - [squamous Cell Carcinoma] of Skin 33
Squamous Cell Carcinoma of the Skin 5
Squamous Cell Epithelioma of Skin 33
Cutaneous Squamous Cell Carcinoma 33
Epidermoid Skin Carcinoma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:3151
NCIt 49 C4819
SNOMED-CT 68 254651007
ICD11 33 1448983042
UMLS 71 C0553723

Summaries for Skin Squamous Cell Carcinoma

Disease Ontology: 11 A skin carcinoma that has material basis in squamous cells.

MalaCards based summary: Skin Squamous Cell Carcinoma, also known as squamous cell carcinoma of skin, is related to squamous cell carcinoma and keratoacanthoma. An important gene associated with Skin Squamous Cell Carcinoma is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Disease and GPCR Pathway. The drugs Carboplatin and Panitumumab have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and lung, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Related Diseases for Skin Squamous Cell Carcinoma

Diseases related to Skin Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 684)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.4 TP53 NRAS KDM4C HRAS HOTAIR ERBB2
2 keratoacanthoma 31.1 TP53 MSH2 MLH1
3 keratinizing squamous cell carcinoma 30.9 TP53 HRAS CDKN2A
4 skin carcinoma 30.9 TP53 NRAS MSH2 MIR21 KDM4C HRAS
5 thyroid cancer, nonmedullary, 1 30.7 TP53 HOTAIR BRAF
6 basal cell nevus syndrome 30.7 TP53 KDM4C HRAS
7 hematologic cancer 30.6 MSH2 MLH1 MIR21 KDM4C HRAS
8 ocular melanoma 30.6 NRAS HRAS CDKN2A
9 salivary gland carcinoma 30.6 TP53 ERBB2 CDKN2A
10 oropharynx cancer 30.6 TP53 MIR21 HRAS ERBB2 CDKN2A
11 human papillomavirus infectious disease 30.6 TP53 MIR21 HRAS ERBB2 CDKN2A
12 suppressor of tumorigenicity 3 30.5 TP53 CDKN2A
13 laryngeal benign neoplasm 30.5 TP53 CDKN2A BCL2L12
14 actinic keratosis 30.5 TP53 KNSTRN CDKN2A
15 lung benign neoplasm 30.5 TP53 HRAS CDKN2A
16 appendix adenocarcinoma 30.5 TP53 MSH6 HRAS
17 neurofibroma 30.5 TP53 RAC1 ERBB2 CDKN2A
18 pancreatic ductal carcinoma 30.4 TP53 HRAS ERBB2 CDKN2A
19 head and neck cancer 30.4 TP53 MIR21 KDM4C HRAS FAT2 ERBB2
20 leukemia, chronic lymphocytic 30.4 TP53 NRAS MIR21 LRRC56 KDM4C HRAS
21 breast adenocarcinoma 30.4 TP53 HRAS ERBB2 CDKN2A
22 small cell cancer of the lung 30.4 TP53 MIR21 HOTAIR CDKN2A
23 nevus, epidermal 30.4 NRAS LRRC56 HRAS
24 langerhans cell histiocytosis 30.4 NRAS HRAS BRAF
25 brain glioma 30.4 TP53 KDM4C ERBB2 CDKN2A
26 thymoma 30.4 TP53 LRRC56 HRAS CDKN2A
27 sebaceous adenoma 30.3 MSH6 MSH2 MLH1
28 mismatch repair cancer syndrome 1 30.3 MSH6 MSH2 MLH1
29 leukemia, acute lymphoblastic 30.3 TP53 MSH2 MIR21 KDM4C HRAS CDKN2A
30 adenoid cystic carcinoma 30.3 TP53 LRRC56 HRAS ERBB2 CDKN2A
31 lynch syndrome 1 30.3 MSH6 MSH2 MLH1
32 lentigines 30.3 RAF1 MSH2 MLH1 BRAF
33 skin benign neoplasm 30.3 TP53 MSH6 MSH2 MLH1 HRAS BRAF
34 leukemia 30.3 TP53 RAF1 NRAS HOTAIR ERBB2 CDKN2A
35 pancreatic ductal adenocarcinoma 30.3 TP53 MIR21 KDM4C HRAS HOTAIR
36 meningioma, familial 30.3 TP53 RAC1 HRAS ERBB2 CDKN2A
37 adenocarcinoma 30.2 TP53 MSH6 MSH2 MLH1 HRAS ERBB2
38 connective tissue disease 30.2 TP53 MIR21 KDM4C HRAS ERBB2 CDKN2A
39 colon adenocarcinoma 30.2 TP53 MSH6 MLH1 HRAS BRAF
40 inherited cancer-predisposing syndrome 30.2 TP53 MSH6 MSH2 MLH1 CDKN2A
41 bap1 tumor predisposition syndrome 30.2 TP53 MSH6 MSH2 MLH1 CDKN2A
42 leukemia, acute myeloid 30.1 TP53 NRAS MIR21 LRRC56 KDM4C HRAS
43 myeloma, multiple 30.1 TP53 NRAS MIR21 LRRC56 KDM4C HRAS
44 muir-torre syndrome 30.1 TP53 MSH6 MSH2 MLH1 HRAS CDKN2A
45 leukemia, chronic myeloid 30.0 TP53 RAF1 NRAS KDM4C HRAS HOTAIR
46 lymphoma, non-hodgkin, familial 30.0 TP53 NRAS MSH2 MIR21 KDM4C BRAF
47 neurofibromatosis 30.0 TP53 NRAS MSH6 MSH2 MLH1 HRAS
48 skin disease 30.0 TP53 NRAS MIR21 KDM4C HRAS ERBB2
49 mucinous adenocarcinoma 30.0 TP53 MSH6 MSH2 MLH1 HRAS ERBB2
50 serous cystadenocarcinoma 30.0 TP53 MSH6 MSH2 MLH1 MIR21 HRAS

Graphical network of the top 20 diseases related to Skin Squamous Cell Carcinoma:



Diseases related to Skin Squamous Cell Carcinoma

Symptoms & Phenotypes for Skin Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

25 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.42 BRAF STK19 HRAS
2 Decreased viability GR00055-A-2 10.42 BRAF STK19 HRAS
3 Decreased viability GR00221-A-1 10.42 RAF1 CDKN2A HRAS NRAS
4 Decreased viability GR00221-A-2 10.42 RAF1 STK19 HRAS
5 Decreased viability GR00221-A-3 10.42 STK19 CDKN2A ERBB2 HRAS NRAS
6 Decreased viability GR00221-A-4 10.42 BRAF STK19 CDKN2A ERBB2
7 Decreased viability GR00249-S 10.42 BRAF
8 Decreased viability GR00301-A 10.42 BRAF MSH2 RAF1 STK19
9 Decreased viability GR00381-A-1 10.42 BRAF
10 Decreased viability GR00402-S-2 10.42 RAF1 STK19
11 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.44 RAF1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.44 BRAF
13 Increased shRNA abundance (Z-score > 2) GR00366-A-150 9.44 KDM4C RAF1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.44 RAF1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-188 9.44 KDM4C
16 Increased shRNA abundance (Z-score > 2) GR00366-A-209 9.44 KDM4C
17 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.44 NRAS
18 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.44 BRAF
19 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.44 RAF1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-72 9.44 KDM4C NRAS RAF1
21 Increased cell migration GR00055-A-3 8.65 STK19

MGI Mouse Phenotypes related to Skin Squamous Cell Carcinoma:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 BRAF CDKN2A ERBB2 HRAS KDM4C KNSTRN
2 neoplasm MP:0002006 10.24 BRAF CDKN2A ERBB2 HRAS KDM4C MLH1
3 endocrine/exocrine gland MP:0005379 10.17 BRAF CDKN2A ERBB2 HRAS KDM4C KNSTRN
4 cellular MP:0005384 10.1 BRAF CDKN2A ERBB2 KDM4C KNSTRN MLH1
5 immune system MP:0005387 10.03 BCL2L12 BRAF CDKN2A KDM4C LRRC56 MLH1
6 no phenotypic analysis MP:0003012 10.02 CDKN2A HOTAIR HRAS KDM4C NRAS RAF1
7 digestive/alimentary MP:0005381 10.01 BRAF CDKN2A ERBB2 HRAS MLH1 MSH2
8 craniofacial MP:0005382 9.91 BRAF ERBB2 HRAS NRAS RAC1 RAF1
9 hematopoietic system MP:0005397 9.77 BCL2L12 BRAF CDKN2A ERBB2 KDM4C KNSTRN
10 respiratory system MP:0005388 9.76 BRAF CDKN2A ERBB2 HRAS LRRC56 MLH1
11 integument MP:0010771 9.44 BRAF CDKN2A ERBB2 HRAS KDM4C LRRC56

Drugs & Therapeutics for Skin Squamous Cell Carcinoma

Drugs for Skin Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
2
Panitumumab Approved, Investigational Phase 2 339177-26-3
3
Peginterferon alfa-2b Approved Phase 2 215647-85-1, 99210-65-8
4
Peginterferon alfa-2a Approved, Investigational Phase 2 198153-51-4
5
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
6
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
7
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
8
Ethanol Approved Phase 2 64-17-5 702
9
Hydrogen peroxide Approved, Vet_approved Phase 2 7722-84-1 784
10
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
11
Ipilimumab Approved Phase 2 477202-00-9
12
Avelumab Approved, Investigational Phase 2 1537032-82-8
13
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
14
Afatinib Approved Phase 2 439081-18-2, 850140-72-6 53445376 10184653
15
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
16
Nivolumab Approved Phase 2 946414-94-4
17
Cetuximab Approved Phase 2 205923-56-4
18
Fluorouracil Approved Phase 2 51-21-8 3385
19
Calcipotriol Approved Phase 2 112965-21-6 5288783
20
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
21
Petrolatum Approved, Investigational Phase 2 8009-03-8
22
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
23
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4 254741536
24
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
25
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
26
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 2 67-97-0, 1406-16-2 5280795 10883523
27
Calcitriol Approved, Nutraceutical Phase 2 32222-06-3 5280453
28
Vilobelimab Investigational Phase 2 2250440-41-4
29 Antiviral Agents Phase 2
30 Interferon alpha-2 Phase 2
31 Interferon-alpha Phase 2
32 ON 01910 Phase 2
33 Anti-Infective Agents Phase 2
34 Anti-Infective Agents, Local Phase 2
35 Immune Checkpoint Inhibitors Phase 2
36 Adjuvants, Immunologic Phase 1, Phase 2
37 Monatide (IMS 3015) Phase 1, Phase 2
38 Analgesics Phase 1, Phase 2
39 Complement System Proteins Phase 2
40 Interleukin-2 Phase 1, Phase 2
41 Analgesics, Non-Narcotic Phase 1, Phase 2
42 Antibodies, Blocking Phase 2
43 Antineoplastic Agents, Immunological Phase 2
44 Pharmaceutical Solutions Phase 1, Phase 2
45 Antibodies, Monoclonal Phase 2
46 Immunoglobulins, Intravenous Phase 2
47 Immunoglobulin G Phase 2
48 Immunosuppressive Agents Phase 2
49 Immunologic Factors Phase 2
50 Hormones Phase 2

Interventional clinical trials:

(show top 50) (show all 146)
# Name Status NCT ID Phase Drugs
1 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
2 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630) Recruiting NCT03833167 Phase 3 Placebo
3 A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Recruiting NCT03969004 Phase 3 Cemiplimab;Placebo
4 A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin Unknown status NCT00423397 Phase 1, Phase 2 gefitinib
5 A Phase II of Study of Nivolumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma Unknown status NCT03834233 Phase 2 Nivolumab
6 An Open Label Multicentric Phase II Study of Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC) Unknown status NCT01129154 Phase 2 infusions of Panitumumab
7 A Phase 2 Study of Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma Completed NCT02218164 Phase 2 Pegylated Interferon alpha-2b;Capecitabine;5-FU
8 Phase II Study of Erlotinib, An Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed NCT01198028 Phase 2 Erlotinib
9 A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
10 Chemoprevention of Squamous Cell Cancer of the Skin in High Risk Patients Completed NCT02347813 Phase 2 Pioglitazone
11 A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia Completed NCT00563290 Phase 2 dasatinib
12 A Phase IIb Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topical Bacteriophage T4 Endonuclease V in Renal Allograft Recipients With a History of Non-melanoma Skin Cancer Completed NCT00089180 Phase 2 liposomal T4N5 lotion
13 A Phase II Study of ZD1839 and Radiation in Patients With Squamous Cell Carcinoma of the Skin Completed NCT00126555 Phase 2 Gefitinib
14 A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed NCT00054691 Phase 2 Iressa
15 Phase II Study of Cetuximab as Monotherapy and First Line Treatment in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Expressing EGFR. Completed NCT00240682 Phase 2 cetuximab
16 Phase II Study of Pembrolizumab (MK-3475) as First Line Single Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin Completed NCT02883556 Phase 2 Pembrolizumab
17 An Open Phase II Study to Assess the Efficacy and Safety of Topical SR-T100® Gel in the Treatment of Human Cutaneous Squamous Cell Carcinoma in Situ (Actinic Keratosis and Bowen's Disease) Completed NCT02085395 Phase 2 SR-T100 ® Gel
18 An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS) Completed NCT00652080 Phase 1, Phase 2 API 31510
19 An Open Label, Dose Escalation Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Patients With Cutaneous Squamous Cell Carcinoma in Situ (isSCC) Completed NCT04293679 Phase 1, Phase 2 STP705
20 Multi-centre, Open-label Study to Determine the Safety and Efficacy of PEP005 0.05% Topical Gel in Patients With Cutaneous Squamous Cell Carcinoma In Situ (SCCIS, Bowen's Disease) Completed NCT00329121 Phase 2 PEP005
21 A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer Currently on Treatment With Anti-PD-(L)1 Without Having Achieved a Complete Remission Completed NCT04144517 Phase 2 ALKS 4230;Pembrolizumab
22 A Phase 2 Double-blind Placebo Randomized Controlled Trial of 30% Topical Application of Hydrogen Peroxide as Neoadjuvant Treatment of Non-melanoma Skin Cancers Prior to Definitive Surgery or Radiation Recruiting NCT04929535 Phase 2 Hydrogen Peroxide 30 % Topical Solution
23 A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors Recruiting NCT02978625 Phase 2
24 Evaluating the PD-1 Checkpoint Inhibitor, Cemiplimab, as Neoadjuvant Therapy in High Risk Localized, Locally Recurrent, and Regionally Advanced Cutaneous Squamous Cell Carcinoma: A Phase II Pilot Study Recruiting NCT04315701 Phase 2
25 A Phase II, Multicenter, Single-Arm Clinical Trial of Radiotherapy and CeMiPlimAb: Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART Recruiting NCT05574101 Phase 2 Cemiplimab
26 Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC) Recruiting NCT03944941 Phase 2 Avelumab;Cetuximab
27 UNresectable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy. A Study to Evaluate the Efficacy and Safety of the Combined Use of Avelumab With Radiation Therapy for the Treatment of Unresectable Cutaneous Squamous Cell Carcinoma Recruiting NCT03737721 Phase 2
28 Camrelizumab Plus Cisplatin in Advanced Cutaneous Squamous Cell Carcinoma: a Single-arm, Open, Single-center Phase II Study Recruiting NCT05490485 Phase 2 Camrelizumab
29 Phase II Study of REGN2810 Prior to Surgery in Patients With Stage II-IV Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck Recruiting NCT03565783 Phase 2
30 A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma Recruiting NCT04050436 Phase 2 Cemiplimab
31 Neo-Adjuvant Atezolizumab Prior to Definitive Surgical Resection of Regionally Metastatic Head &Amp; Neck Cutaneous Squamous Cell Carcinoma With an Unknown or Historic Primary Site: A Window Trial Recruiting NCT05110781 Phase 2
32 An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors Recruiting NCT04305795 Phase 1, Phase 2
33 A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination With Anti-PD1 Therapy in Patients With Advanced NSCLC or Squamous Head and Neck Cancer Recruiting NCT02955290 Phase 1, Phase 2
34 Quad-Shot Radiotherapy in Combination With Immune Checkpoint Inhibition for Advanced/Recurrent Head and Neck Cancer Recruiting NCT04454489 Phase 2 Pembrolizumab (immunotherapy)
35 Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Patients Prior to Standard of Care Surgery; the MATISSE Trial Recruiting NCT04620200 Phase 2 Nivolumab;Ipilimumab
36 ML42362: Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma Recruiting NCT04710498 Phase 2 Atezolizumab
37 Open Label, Multicenter Phase II Study of the C5a Antibody IFX-1 Alone or IFX-1 + Pembrolizumab in Patients With PD-1 or PD-L1 Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) Recruiting NCT04812535 Phase 2 IFX-1;IFX-1 + pembrolizumab combination therapy
38 Phase II Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) Recruiting NCT04808999 Phase 2 Pembrolizumab Injection
39 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Patients With Cutaneous Squamous Cell Carcinoma in Situ (isSCC) Recruiting NCT04844983 Phase 2 STP705
40 A Multi-Center Phase II Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma Recruiting NCT04807777 Phase 2 Ruxolitinib
41 A Single-arm, Open-Label, Multicenter Phase II Clinical Study to Evaluate Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) in Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) Recruiting NCT05238363 Phase 2 HLX07
42 Phase 2, Open-label, Single-arm, Window of Opportunity Study of ASP-1929 Photoimmunotherapy With Fluorescence Imaging in Patients With Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma Recruiting NCT05182866 Phase 2
43 Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma Recruiting NCT05070403 Phase 2 Afatinib 40 MG
44 An Open Label, Dose Escalation Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Subjects With Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC) Recruiting NCT05421013 Phase 1, Phase 2 STP705
45 A Phase 2 Study of De-escalation in Resectable, Locally Advanced Cutaneous Squamous Cell Carcinoma With the Use of Neoadjuvant Pembrolizumab - DESQUAMATE Recruiting NCT05025813 Phase 2 Pembrolizumab
46 A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Recruiting NCT05565417 Phase 1, Phase 2 IMT-009
47 A Phase 1b/2a, Open Label Study to Evaluate Anti-tumor Efficacy and Safety of rhIL-7-hyFc (NT-I7) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Anti-PD-1/PD-L1 naïve or Relapsed/Refractory High-risk Skin Cancers Recruiting NCT03901573 Phase 1, Phase 2 NT-I7;atezolizumab
48 A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors Recruiting NCT04301011 Phase 1, Phase 2
49 A Phase II, Single Arm Study Investigating Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in High Risk, Surgically Resectable, Stage III Cutaneaous Squamous Cell Carcinoma Recruiting NCT04632433 Phase 2 Cemiplimab
50 A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 Monotherapy or in Combination With Cetuximab as a Salvage Regimen for Solid Tumors Recruiting NCT04616196 Phase 1, Phase 2 NKTR-255;Cetuximab

Search NIH Clinical Center for Skin Squamous Cell Carcinoma

Genetic Tests for Skin Squamous Cell Carcinoma

Anatomical Context for Skin Squamous Cell Carcinoma

Organs/tissues related to Skin Squamous Cell Carcinoma:

MalaCards : Skin, Lymph Node, Lung, Kidney, Breast, Thyroid, Liver

Publications for Skin Squamous Cell Carcinoma

Articles related to Skin Squamous Cell Carcinoma:

(show top 50) (show all 4070)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
2
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
3
Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. 5
22726224 2012
4
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. 5
22256804 2012
5
Thirteen cancers associated with HIV infection in a Black South African cancer patient population (1995-2016). 62
36054877 2023
6
Gallic acid has an inhibitory effect on skin squamous cell carcinoma and acts on the heat shock protein HSP90AB1. 62
36375658 2023
7
Squamous Cell Carcinoma: An Update in Staging, Management, and Postoperative Surveillance Strategies. 62
36410970 2023
8
Pristimerin mediated anticancer effects and sensitization of human skin cancer cells through modulation of MAPK signaling pathways. 62
36411635 2022
9
Epidemiology and treatment outcomes of cutaneous squamous cell carcinoma extending to the temporal bone. 62
36082824 2022
10
Prospective study evaluating the personal history of rosacea and risk of cutaneous squamous cell carcinoma among women in the United States. 62
36089188 2022
11
Are YouTube videos on cutaneous squamous cell carcinoma a useful and reliable source for patients? 62
36464812 2022
12
Rate and Characteristics of Incompletely Excised Cutaneous Squamous Cell Carcinoma: A Dermatological Daily Practice Multicenter Prospective Cohort Study. 62
36194767 2022
13
DANGER: what clinicians need to know about aggressive head and neck cutaneous squamous cell carcinoma. 62
36463501 2022
14
A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma. 62
36274573 2022
15
Defining the Molecular Landscape of Cancer-Associated Stroma in Cutaneous Squamous Cell Carcinoma. 62
35850206 2022
16
Lack of documentation of lymph node examination in patients with squamous cell carcinoma of the lower lip. 62
34562138 2022
17
Addendum: Mutually exclusive lymphangiogenesis or perineural infiltration in human skin squamous-cell carcinoma. 62
36473116 2022
18
Cutaneous horn due to cutaneous squamous cell carcinoma. 62
36379697 2022
19
Value of permanent pathology for debulk and Mohs specimens during Mohs micrographic surgery for cutaneous squamous cell carcinoma: A retrospective cohort study. 62
35753550 2022
20
A case of head and neck cutaneous squamous cell carcinoma highlighting aggressive perineural features. 62
36189160 2022
21
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma. 62
36455990 2022
22
[Cutaneous squamous cell carcinoma of the head and neck]. 62
36455599 2022
23
Immune status does not independently influence cutaneous squamous cell carcinoma metastasis and death when stratified by tumor stage: A dual-center retrospective cohort analysis of primary N0 disease. 62
36063987 2022
24
Towards less mutilating treatments in patients with advanced non-melanoma skin cancers by earlier use of immune checkpoint inhibitors. 62
36257534 2022
25
Characterizing Skin Cancer in Transplant Recipients by Fitzpatrick Skin Phototype. 62
36469283 2022
26
Prevalence of 13 polyomaviruses in actinic keratosis and matched healthy skin samples of immunocompetent individuals. 62
36457033 2022
27
Comparison of reflectance confocal microscopy and line-field optical coherence tomography for the identification of keratinocyte skin tumours. 62
36424847 2022
28
An Epidemiological Update on Indoor Tanning and the Risk of Skin Cancers. 62
36421352 2022
29
Features and clinical significance of tertiary lymphoid structure in cutaneous squamous cell carcinoma. 62
35881141 2022
30
Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients. 62
36073945 2022
31
S1-Guideline: Microscopically controlled surgery. 62
36448272 2022
32
Genetically Predicted Serum Vitamin C Levels and Cutaneous Squamous Cell Carcinoma Risk. 62
36343677 2022
33
Cutaneous squamous cell carcinoma in an autosomal-recessive Adams-Oliver syndrome patient with a novel frameshift pathogenic variant in the EOGT gene. 62
36059114 2022
34
Cutaneous Squamous Cell Carcinoma and Mortality in End-Stage Renal Disease. 62
36403674 2022
35
Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer. 62
36251220 2022
36
Follow-up of Patients With Keratinocyte Carcinoma: A Systematic Review of Clinical Practice Guidelines. 62
36322063 2022
37
Complete response of locally advanced cutaneous squamous cell carcinoma of the eyelid to topical imiquimod 3.75. 62
36066074 2022
38
Recurrent bilateral cutaneous squamous cell carcinoma arising within hypertrophic lichen planus with metastasis while on cemiplimab. 62
36193242 2022
39
Locally Advanced Cutaneous Squamous Cell Carcinoma Treated With Immunotherapy in a Dermatology Department. 62
36370835 2022
40
Modelling cutaneous squamous cell carcinoma for laboratory research. 62
36373888 2022
41
In-transit Metastases of Cutaneous Squamous Cell Carcinoma: A Single Institution Case Series. 62
36403751 2022
42
Humoral hypercalcaemia of malignancy associated with a gigantic cutaneous squamous cell carcinoma. 62
36323452 2022
43
Anti PD-1 Checkpoint Inhibitor As a First-Line Treatment for Advanced Cutaneous Squamous Cell Carcinoma. 62
36441840 2022
44
Twist1 as a target for prevention of cutaneous squamous cell carcinoma. 62
36373194 2022
45
Alkannin exerts antitumor properties in cutaneous squamous cell carcinoma by inducing apoptosis and shifting the M1/M2 polarization of tumor-associated macrophages by upregulating PTEN. 62
36367154 2022
46
Characterisation of the immune microenvironment of cutaneous squamous cell carcinoma in immunosuppression. 62
35861124 2022
47
Chemoprevention of cutaneous squamous cell carcinoma and its precursors in solid organ transplant recipients using topical sirolimus: A randomized, double-blind, placebo-controlled pilot trial. 62
35219749 2022
48
Cutaneous Squamous Cell Carcinoma With Orbital Extension. 62
36201188 2022
49
Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta-analysis. 62
36329570 2022
50
The Potentiation of Radiosensitization by Concomitant Treatment With Radiation Therapy and a PDL-1 Inhibitor in Cutaneous Squamous Cell Carcinoma. 62
36131995 2022

Variations for Skin Squamous Cell Carcinoma

ClinVar genetic disease variations for Skin Squamous Cell Carcinoma:

5 (show top 50) (show all 107)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 KNSTRN NM_033286.4(KNSTRN):c.71C>T (p.Ser24Phe) SNV Likely Pathogenic
376441 rs868438023 GRCh37: 15:40675107-40675107
GRCh38: 15:40382906-40382906
2 RAC1 NM_006908.5(RAC1):c.86C>T (p.Pro29Leu) SNV Likely Pathogenic
376512 rs1057519948 GRCh37: 7:6426893-6426893
GRCh38: 7:6387262-6387262
3 CRNKL1 NM_001278628.2(CRNKL1):c.-101C>T SNV Likely Pathogenic
376389 rs1057519885 GRCh37: 20:20033087-20033087
GRCh38: 20:20052443-20052443
4 RAC1 NM_006908.5(RAC1):c.85C>A (p.Pro29Thr) SNV Likely Pathogenic
376513 rs1057519874 GRCh37: 7:6426892-6426892
GRCh38: 7:6387261-6387261
5 CDKN2A NM_000077.5(CDKN2A):c.341C>A (p.Pro114His) SNV Likely Pathogenic
376383 rs121913386 GRCh37: 9:21971017-21971017
GRCh38: 9:21971018-21971018
6 CDKN2A NM_000077.5(CDKN2A):c.340C>A (p.Pro114Thr) SNV Likely Pathogenic
376382 rs104894104 GRCh37: 9:21971018-21971018
GRCh38: 9:21971019-21971019
7 BRAF NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg) SNV Likely Pathogenic
13970 rs121913357 GRCh37: 7:140481403-140481403
GRCh38: 7:140781603-140781603
8 BRAF NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) SNV Likely Pathogenic
13971 rs121913355 GRCh37: 7:140481402-140481402
GRCh38: 7:140781602-140781602
9 HRAS, LRRC56 NM_005343.4(HRAS):c.37G>A (p.Gly13Ser) SNV Likely Pathogenic
376323 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
10 CDKN2A NM_000077.5(CDKN2A):c.150G>T (p.Gln50His) SNV Likely Pathogenic
376384 rs1057519882 GRCh37: 9:21974677-21974677
GRCh38: 9:21974678-21974678
11 ERBB2 NM_004448.4(ERBB2):c.929C>T (p.Ser310Phe) SNV Likely Pathogenic
376189 rs1057519816 GRCh37: 17:37868208-37868208
GRCh38: 17:39711955-39711955
12 HRAS, LRRC56 NM_005343.4(HRAS):c.38G>T (p.Gly13Val) SNV Likely Pathogenic
180848 rs104894226 GRCh37: 11:534285-534285
GRCh38: 11:534285-534285
13 BRAF NM_004333.6(BRAF):c.1406G>T (p.Gly469Val) SNV Likely Pathogenic
44803 rs121913355 GRCh37: 7:140481402-140481402
GRCh38: 7:140781602-140781602
14 RAC1 NM_006908.5(RAC1):c.85C>T (p.Pro29Ser) SNV Likely Pathogenic
376362 rs1057519874 GRCh37: 7:6426892-6426892
GRCh38: 7:6387261-6387261
15 CDKN2A NM_000077.5(CDKN2A):c.247C>G (p.His83Asp) SNV Likely Pathogenic
376380 rs121913385 GRCh37: 9:21971111-21971111
GRCh38: 9:21971112-21971112
16 HRAS, LRRC56 NM_005343.4(HRAS):c.183G>T (p.Gln61His) SNV Likely Pathogenic
376318 rs121913496 GRCh37: 11:533873-533873
GRCh38: 11:533873-533873
17 HRAS, LRRC56 NM_005343.4(HRAS):c.182A>T (p.Gln61Leu) SNV Likely Pathogenic
376033 rs121913233 GRCh37: 11:533874-533874
GRCh38: 11:533874-533874
18 ERBB2 NM_004448.4(ERBB2):c.929C>A (p.Ser310Tyr) SNV Likely Pathogenic
376188 rs1057519816 GRCh37: 17:37868208-37868208
GRCh38: 17:39711955-39711955
19 TP53 NM_000546.6(TP53):c.856G>C (p.Glu286Gln) SNV Likely Pathogenic
376591 rs786201059 GRCh37: 17:7577082-7577082
GRCh38: 17:7673764-7673764
20 TP53 NM_000546.6(TP53):c.746G>T (p.Arg249Met) SNV Likely Pathogenic
376653 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
21 TP53 NM_000546.6(TP53):c.722C>A (p.Ser241Tyr) SNV Likely Pathogenic
376663 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
22 TP53 NM_000546.6(TP53):c.842A>C (p.Asp281Ala) SNV Likely Pathogenic
376589 rs587781525 GRCh37: 17:7577096-7577096
GRCh38: 17:7673778-7673778
23 TP53 NM_000546.6(TP53):c.706T>G (p.Tyr236Asp) SNV Likely Pathogenic
142183 rs587782289 GRCh37: 17:7577575-7577575
GRCh38: 17:7674257-7674257
24 TP53 NM_000546.6(TP53):c.721T>C (p.Ser241Pro) SNV Likely Pathogenic
376664 rs1057520002 GRCh37: 17:7577560-7577560
GRCh38: 17:7674242-7674242
25 TP53 NM_000546.6(TP53):c.809T>G (p.Phe270Cys) SNV Likely Pathogenic
376597 rs1057519986 GRCh37: 17:7577129-7577129
GRCh38: 17:7673811-7673811
26 TP53 NM_000546.6(TP53):c.857A>T (p.Glu286Val) SNV Likely Pathogenic
376592 rs1057519985 GRCh37: 17:7577081-7577081
GRCh38: 17:7673763-7673763
27 TP53 NM_000546.6(TP53):c.857A>G (p.Glu286Gly) SNV Likely Pathogenic
376590 rs1057519985 GRCh37: 17:7577081-7577081
GRCh38: 17:7673763-7673763
28 TP53 NM_000546.6(TP53):c.647T>G (p.Val216Gly) SNV Likely Pathogenic
376671 rs1057520004 GRCh37: 17:7578202-7578202
GRCh38: 17:7674884-7674884
29 HRAS, LRRC56 NM_005343.4(HRAS):c.37G>C (p.Gly13Arg) SNV Likely Pathogenic
35554 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
30 TP53 NM_000546.6(TP53):c.373A>C (p.Thr125Pro) SNV Likely Pathogenic
376666 rs1057520003 GRCh37: 17:7579314-7579314
GRCh38: 17:7675996-7675996
31 TP53 NM_000546.6(TP53):c.841G>T (p.Asp281Tyr) SNV Likely Pathogenic
376585 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
32 TP53 NM_000546.6(TP53):c.638G>T (p.Arg213Leu) SNV Likely Pathogenic
376650 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
33 TP53 NM_000546.6(TP53):c.839G>T (p.Arg280Ile) SNV Likely Pathogenic
161517 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
34 TP53 NM_000546.6(TP53):c.815T>A (p.Val272Glu) SNV Likely Pathogenic
376673 rs876660333 GRCh37: 17:7577123-7577123
GRCh38: 17:7673805-7673805
35 TP53 NM_000546.6(TP53):c.810T>G (p.Phe270Leu) SNV Likely Pathogenic
376595 rs1057519987 GRCh37: 17:7577128-7577128
GRCh38: 17:7673810-7673810
36 TP53 NM_000546.6(TP53):c.374C>A (p.Thr125Lys) SNV Likely Pathogenic
216465 rs786201057 GRCh37: 17:7579313-7579313
GRCh38: 17:7675995-7675995
37 TP53 NM_000546.6(TP53):c.857A>C (p.Glu286Ala) SNV Likely Pathogenic
376593 rs1057519985 GRCh37: 17:7577081-7577081
GRCh38: 17:7673763-7673763
38 HRAS, LRRC56 NM_005343.4(HRAS):c.34G>T (p.Gly12Cys) SNV Likely Pathogenic
12613 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
39 HRAS, LRRC56 NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Likely Pathogenic
12603 rs104894230 GRCh37: 11:534288-534288
GRCh38: 11:534288-534288
40 HRAS, LRRC56 NM_005343.4(HRAS):c.37G>T (p.Gly13Cys) SNV Likely Pathogenic
12606 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
41 TP53 NM_000546.6(TP53):c.722C>T (p.Ser241Phe) SNV Likely Pathogenic
12359 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
42 TP53 NM_000546.6(TP53):c.647T>A (p.Val216Glu) SNV Likely Pathogenic
376672 rs1057520004 GRCh37: 17:7578202-7578202
GRCh38: 17:7674884-7674884
43 TP53 NM_000546.6(TP53):c.845G>C (p.Arg282Pro) SNV Likely Pathogenic
376659 rs730882008 GRCh37: 17:7577093-7577093
GRCh38: 17:7673775-7673775
44 TP53 NM_000546.6(TP53):c.535C>T (p.His179Tyr) SNV Likely Pathogenic
127815 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
45 TP53 NM_000546.6(TP53):c.832C>G (p.Pro278Ala) SNV Likely Pathogenic
376645 rs17849781 GRCh37: 17:7577106-7577106
GRCh38: 17:7673788-7673788
46 TP53 NM_000546.6(TP53):c.841G>C (p.Asp281His) SNV Likely Pathogenic
376588 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
47 TP53 NM_000546.6(TP53):c.638G>C (p.Arg213Pro) SNV Likely Pathogenic
231214 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
48 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln) SNV Likely Pathogenic
135359 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
49 TP53 NM_000546.6(TP53):c.537T>G (p.His179Gln) SNV Likely Pathogenic
376607 rs876660821 GRCh37: 17:7578393-7578393
GRCh38: 17:7675075-7675075
50 TP53 NM_000546.6(TP53):c.746G>A (p.Arg249Lys) SNV Likely Pathogenic
142241 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217

Cosmic variations for Skin Squamous Cell Carcinoma:

8 (show top 50) (show all 15557)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM108405939 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.316C>T p.P106S 16:31064213-31064213 19
2 COSM131595377 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.947C>T p.S316L 16:31062050-31062050 19
3 COSM101742625 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.878C>T p.S293L 16:31062050-31062050 19
4 COSM131595368 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.1886C>T p.P629L 16:31061111-31061111 19
5 COSM87498632 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.247C>T p.P83S 16:31064213-31064213 19
6 COSM101742795 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.247C>T p.P83S 16:31064213-31064213 19
7 COSM133260761 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.878C>T p.S293L 16:31062050-31062050 19
8 COSM132355968 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.1817C>T p.P606L 16:31061111-31061111 19
9 COSM132355981 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.878C>T p.S293L 16:31062050-31062050 19
10 COSM131595526 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.316C>T p.P106S 16:31064213-31064213 19
11 COSM87498178 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.1817C>T p.P606L 16:31061111-31061111 19
12 COSM101742614 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.1817C>T p.P606L 16:31061111-31061111 19
13 COSM133260750 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.1817C>T p.P606L 16:31061111-31061111 19
14 COSM133260941 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.247C>T p.P83S 16:31064213-31064213 19
15 COSM108405783 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.1886C>T p.P629L 16:31061111-31061111 19
16 COSM108405799 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.947C>T p.S316L 16:31062050-31062050 19
17 COSM132356152 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.247C>T p.P83S 16:31064213-31064213 19
18 COSM87498195 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.878C>T p.S293L 16:31062050-31062050 19
19 COSM101590418 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13:20002948-20002948 19
20 COSM143109510 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13:20002948-20002948 19
21 COSM101612017 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13:20002948-20002948 19
22 COSM107139107 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.683A>C p.K228T 3:147395971-147395971 19
23 COSM101870708 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.522C>T p.F174= 3:147396018-147396018 19
24 COSM129142467 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.672C>T p.F224= 3:147396018-147396018 19
25 COSM118697764 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.71-4725A>C p.? 3:147395971-147395971 19
26 COSM115494047 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.569A>C p.K190T 3:147395971-147395971 19
27 COSM118700792 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.71-4772C>T p.? 3:147396018-147396018 19
28 COSM115497576 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.282C>G p.A94= 3:147396258-147396258 19
29 COSM129137619 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.135G>A p.K45= 3:147403964-147403964 19
30 COSM129143394 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.1026G>C p.P342= 3:147391059-147391059 19
31 COSM115492982 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.-15-1152G>A p.? 3:147403964-147403964 19
32 COSM107143716 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.396C>G p.A132= 3:147396258-147396258 19
33 COSM129143406 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.432C>G p.A144= 3:147396258-147396258 19
34 COSM101872056 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.282C>G p.A94= 3:147396258-147396258 19
35 COSM120258678 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.-16G>A p.? 3:147403964-147403964 19
36 COSM101866693 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.569A>C p.K190T 3:147395971-147395971 19
37 COSM101864973 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.-15-1152G>A p.? 3:147403964-147403964 19
38 COSM115497565 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.876G>C p.P292= 3:147391059-147391059 19
39 COSM120264120 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.876G>C p.P292= 3:147391059-147391059 19
40 COSM107142798 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.636C>T p.F212= 3:147396018-147396018 19
41 COSM101867690 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.314T>G p.V105G 3:147396226-147396226 19
42 COSM120260940 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.314T>G p.V105G 3:147396226-147396226 19
43 COSM118702064 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.71-5012C>G p.? 3:147396258-147396258 19
44 COSM129140070 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.464T>G p.V155G 3:147396226-147396226 19
45 COSM120260164 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.569A>C p.K190T 3:147395971-147395971 19
46 COSM118698551 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.71-4980T>G p.? 3:147396226-147396226 19
47 COSM101872044 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.876G>C p.P292= 3:147391059-147391059 19
48 COSM118702056 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.258G>C p.P86= 3:147391059-147391059 19
49 COSM129139322 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.719A>C p.K240T 3:147395971-147395971 19
50 COSM107143709 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.990G>C p.P330= 3:147391059-147391059 19

Expression for Skin Squamous Cell Carcinoma

Search GEO for disease gene expression data for Skin Squamous Cell Carcinoma.

Pathways for Skin Squamous Cell Carcinoma

Pathways related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 101)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 BRAF CDKN2A ERBB2 HRAS MLH1 MSH2
2
Show member pathways
13.75 TP53 RAF1 RAC1 NRAS HRAS ERBB2
3
Show member pathways
13.5 TP53 RAF1 RAC1 NRAS MSH6 HRAS
4
Show member pathways
13.12 TP53 RAF1 RAC1 NRAS HRAS BRAF
5
Show member pathways
12.94 RAF1 RAC1 NRAS HRAS BRAF
6
Show member pathways
12.92 RAF1 RAC1 NRAS HRAS ERBB2 BRAF
7
Show member pathways
12.91 RAF1 RAC1 NRAS HRAS BRAF
8
Show member pathways
12.91 RAF1 RAC1 NRAS HRAS BRAF
9
Show member pathways
12.89 RAF1 RAC1 NRAS HRAS BRAF
10 12.88 BRAF ERBB2 HRAS NRAS RAC1
11
Show member pathways
12.88 TP53 RAF1 RAC1 NRAS HRAS BRAF
12
Show member pathways
12.82 HRAS NRAS RAC1 RAF1 TP53
13
Show member pathways
12.79 RAF1 RAC1 NRAS HRAS BRAF
14
Show member pathways
12.75 TP53 RAF1 RAC1 NRAS MSH6 MSH2
15
Show member pathways
12.72 RAF1 RAC1 NRAS HRAS BRAF
16
Show member pathways
12.72 TP53 RAF1 NRAS HRAS BRAF
17
Show member pathways
12.71 RAF1 NRAS HRAS CDKN2A BRAF
18
Show member pathways
12.62 TP53 RAC1 NRAS MSH2 HRAS ERBB2
19 12.56 TP53 MSH6 MSH2 MLH1 CDKN2A
20
Show member pathways
12.48 TP53 NRAS HRAS ERBB2
21
Show member pathways
12.46 RAF1 RAC1 NRAS HRAS
22
Show member pathways
12.45 RAF1 RAC1 HRAS BRAF
23
Show member pathways
12.45 RAF1 RAC1 NRAS HRAS
24
Show member pathways
12.44 TP53 RAF1 RAC1 HRAS ERBB2 BRAF
25
Show member pathways
12.43 TP53 RAF1 NRAS HRAS ERBB2 BRAF
26
Show member pathways
12.42 RAF1 RAC1 NRAS HRAS ERBB2 BRAF
27
Show member pathways
12.38 RAF1 RAC1 HRAS ERBB2
28
Show member pathways
12.37 TP53 RAF1 RAC1 HRAS
29
Show member pathways
12.37 RAF1 RAC1 NRAS HRAS
30 12.34 BRAF HRAS NRAS RAC1 RAF1 TP53
31 12.33 RAF1 RAC1 HRAS ERBB2 BRAF
32 12.3 RAF1 RAC1 NRAS HRAS
33
Show member pathways
12.3 RAF1 RAC1 NRAS HRAS BRAF
34
Show member pathways
12.27 RAF1 RAC1 NRAS HRAS
35 12.23 TP53 MSH6 MSH2 MLH1 BRAF
36
Show member pathways
12.23 TP53 RAF1 NRAS HRAS ERBB2 BRAF
37
Show member pathways
12.21 ERBB2 HRAS NRAS RAC1
38
Show member pathways
12.2 TP53 RAF1 HRAS CDKN2A
39 12.2 RAF1 RAC1 NRAS BRAF
40
Show member pathways
12.19 RAF1 NRAS HRAS BRAF
41
Show member pathways
12.19 TP53 RAF1 RAC1 NRAS HRAS ERBB2
42 12.17 BRAF MSH2 MSH6 RAC1 TP53
43
Show member pathways
12.14 RAF1 RAC1 NRAS HRAS BRAF
44 12.12 RAF1 RAC1 NRAS BRAF
45 12.12 TP53 RAF1 RAC1 ERBB2 BRAF
46 12.08 HRAS NRAS RAC1 RAF1
47
Show member pathways
12.07 TP53 RAF1 ERBB2 BRAF
48 12.02 RAF1 RAC1 HRAS CDKN2A
49
Show member pathways
12.02 TP53 STK19 RAF1 RAC1 NRAS MSH6
50 12 RAF1 RAC1 NRAS BRAF

GO Terms for Skin Squamous Cell Carcinoma

Cellular components related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatch repair complex GO:0032300 9.13 MSH2 MLH1
2 MutSalpha complex GO:0032301 8.92 MSH6 MSH2

Biological processes related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.16 TP53 MIR21 HRAS ERBB2 CDKN2A BRAF
2 MAPK cascade GO:0000165 10.14 BRAF HRAS NRAS RAF1
3 Ras protein signal transduction GO:0007265 10.01 TP53 NRAS HRAS CDKN2A
4 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.97 MSH6 MSH2 MLH1
5 intrinsic apoptotic signaling pathway GO:0097193 9.95 TP53 MSH6 HRAS
6 mismatch repair GO:0006298 9.91 MLH1 MSH2 MSH6
7 positive regulation of helicase activity GO:0051096 9.85 MSH6 MSH2
8 cellular response to gamma radiation GO:0071480 9.85 TP53 MIR21 HRAS
9 determination of adult lifespan GO:0008340 9.85 TP53 MSH6 MSH2
10 positive regulation of isotype switching to IgA isotypes GO:0048298 9.81 MSH2 MLH1
11 isotype switching GO:0045190 9.8 MSH6 MSH2 MLH1
12 negative regulation of immature T cell proliferation in thymus GO:0033088 9.7 ERBB2 CDKN2A
13 maintenance of DNA repeat elements GO:0043570 9.67 MSH6 MSH2
14 somatic hypermutation of immunoglobulin genes GO:0016446 9.63 MSH6 MSH2 MLH1
15 positive regulation of protein phosphorylation GO:0001934 9.61 RAF1 RAC1 MIR21 HRAS ERBB2 BRAF
16 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.43 MLH1 MSH2
17 somatic recombination of immunoglobulin gene segments GO:0016447 9.02 MSH6 MSH2 MLH1

Molecular functions related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 10.1 KDM4C MLH1 MSH2 MSH6 RAC1 RAF1
2 G protein activity GO:0003925 9.91 RAC1 NRAS HRAS
3 ATP-dependent DNA damage sensor activity GO:0140664 9.8 MSH6 MSH2 MLH1
4 MutLalpha complex binding GO:0032405 9.78 MSH6 MSH2
5 oxidized purine DNA binding GO:0032357 9.76 MSH6 MSH2
6 single guanine insertion binding GO:0032142 9.71 MSH6 MSH2
7 single thymine insertion binding GO:0032143 9.67 MSH6 MSH2
8 nucleotide binding GO:0000166 9.65 STK19 RAF1 RAC1 NRAS MSH6 MSH2
9 mismatched DNA binding GO:0030983 9.55 MSH6 MSH2 MLH1
10 guanine/thymine mispair binding GO:0032137 9.1 MSH6 MSH2 MLH1

Sources for Skin Squamous Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....